Generation of diffuse large B cell lymphoma-associated antigen-specific Vα6/Vα13+T cells by TCR gene transfer

Journal of Hematology and Oncology

Volumn 4, Issue , 2011, Pages

  Yin, Qingsong ^a   Zha, Xianfeng ^a   Yang, Lijian ^a   Chen, Shaohua ^a   Zhou, Yubing ^b   Wu, Xiuli ^a   Li, Yangqiu ^a,b  

^a MEDICAL COLLEGE OF JINAN UNIVERSITY   (China)

^b JINAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

LACTATE DEHYDROGENASE; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; LYMPHOCYTE ANTIGEN RECEPTOR;

ARTICLE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; GENE CASSETTE; GENE TRANSFER; LARGE CELL LYMPHOMA; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN FUNCTION; RADIOENZYMATIC ASSAY; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE; WESTERN BLOTTING; B CELL LYMPHOMA; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; GENETICS; HUMAN; IMMUNOLOGY; TUMOR CELL LINE;

CELL LINE, TUMOR; GENE TRANSFER TECHNIQUES; HUMANS; LYMPHOMA, B-CELL; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; TRANSDUCTION, GENETIC; TRANSFECTION;

EID: 78651061145     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-4-2     Document Type: Article

References (34)

1. A new era for cancer immunotherapy based on the genes that encode cancer antigens. SA Rosenberg, Immunity 1999 10 281 287 10.1016/S1074-7613(00)80028-X 10204484
2. Cancer immunotherapy: A treatment for the masses. JN Blattman PD Greenberg, Science 2004 305 200 205 10.1126/science.1100369 15247469
3. Donor leukocyte infusions to treat hematologic malignancy relapse following allo-SCT in a pediatric population. JE Levine AJ Barrett MJ Zhang M Arora MA Pulsipher N Bunin J Fort F Loberiza D Porter S Giralt W Drobyski D Wang S Pavletic O Ringden MM Horowitz RJ Collins, Bone Marrow Transplant 2008 42 201 205 10.1038/bmt.2008.135 18490913
4. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: A retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. C Schmid M Labopin A Nagler M Bornhäuser J Finke A Fassas L Volin G Gürman J Maertens P Bordigoni E Holler G Ehninger E Polge NC Gorin HJ Kolb V Rocha, J Clin Oncol 2007 25 4938 4945 10.1200/JCO.2007.11.6053 17909197
5. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. DL Porter RH Collins Jr C Hardy NA Kernan WR Drobyski S Giralt ME Flowers J Casper A Leahey P Parker R Mick B Bate-Boyle R King JH Antin, Blood 2000 95 1214 1221 10666193
6. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. SA Rosenberg P Spiess R Lafreniere, Science 1986 233 1318 1321 10.1126/science.3489291 3489291
7. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. ME Dudley JR Wunderlich JC Yang RM Sherry SL Topalian NP Restifo RE Royal MM Pelletier J Gea-Banacloche MR Robinson DM Berman AC Filie A Abati SA Rosenberg, J Clin Oncol 2005 23 2346 2357 10.1200/JCO.2005.00.240 15800326
8. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. ME Dudley JR Wunderlich PF Robbins JC Yang P Hwu DJ Schwartzentruber SL Topalian R Sherry NP Restifo AM Hubicki MR Robinson M Raffeld P Duray CA Seipp L Rogers-Freezer KE Morton SA Mavroukakis DE White SA Rosenberg, Science 2002 298 850 854 10.1126/science.1076514 12242449
9. A novel proteoliposomal vaccine elicits potent antitumor immunity in mice. MC Popescu RJ Robb MM Batenjany LT Boni ME Neville RW Pennington SS Neelapu LW Kwak, Blood 2007 109 5407 5410 10.1182/blood-2006-08-039446 17351111
10. Phase I study of adoptive T-cell therapy using antigen-specific CD8+T cells for the treatment of patients with metastatic melanoma. A Mackensen N Meidenbauer S Vogl M Laumer J Berger R Andreesen, J Clin Oncol 2006 24 5060 5069 10.1200/JCO.2006.07.1100 17075125
11. Immunotherapy through TCR gene transfer. HW Kessels MC Wolkers MD van den Boom MA van der Valk TN Schumacher, Nat Immunol 2001 2 957 61 10.1038/ni1001-957 11577349
12. T-cell receptor gene transfer for the treatment of leukemia and other tumors. MHM Heemskerk, Haematologica 2010 95 15 19 10.3324/haematol.2009.016022 20065080
13. Genetic engineering of virus-specific T cells with T-cell receptors recognizing minor histocompatibility antigens for clinical application. M Griffioen HM van Egmond H Barnby-Porritt MA van der Hoorn RS Hagedoorn MG Kester N Schwabe R Willemze JH Falkenburg MH Heemskerk, Haematologica 2008 93 1535 1543 10.3324/haematol.13067 18768532
14. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. TM Clay MC Custer J Sachs P Hwu SA Rosenberg MI Nishimura, J Immunol 1999 163 507 513 10384155
15. Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells. SA Xue L Gao D Hart R Gillmore W Qasim A Thrasher J Apperley B Engels W Uckert E Morris H Stauss, Blood 2005 106 3062 3067 10.1182/blood-2005-01-0146 16020516
16. Cooperation of human tumor-reactive CD4+ and CD8+T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. J Kuball FW Schmitz RH Voss EA Ferreira R Engel P Guillaume S Strand P Romero C Huber LA Sherman M Theobald, Immunity 2005 22 117 129 10.1016/j.immuni.2004.12. 005 15664164
17. Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes. LJ Cooper M Kalos DA Lewinsohn SR Riddell PD Greenberg, J Virol 2000 74 8207 8212 10.1128/JVI.74.17.8207-8212.2000 10933734
18. Retroviral transfer of T-cell receptor genes produces cells with a broad range of lytic activity. RJ Orentas LA Bircher S Roskopf, Scand J Immunol 2003 58 33 42 10.1046/j.1365-3083.2003.01277.x 12828556
19. Cancer regression in patients after transfer of genetically engineered lymphocytes. RA Morgan ME Dudley JR Wunderlich MS Hughes JC Yang RM Sherry RE Royal SL Topalian US Kammula NP Restifo Z Zheng A Nahvi CR de Vries LJ Rogers-Freezer SA Mavroukakis SA Rosenberg, Science 2006 314 126 129 10.1126/science.1129003 16946036
20. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. TM Habermann EA Weller VA Morrison RD Gascoyne PA Cassileth JB Cohn SR Dakhil B Woda RI Fisher BA Peterson SJ Horning, J Clin Oncol 2006 24 3121 3127 10.1200/JCO.2005.05.1003 16754935
21. Development of a Wilms' tumor antigen-specific T-cell receptor for clinical trials: Engineered patient's T cells can eliminate autologous leukemia blasts in NOD/SCID mice. SA Xue L Gao S Thomas DP Hart JZ Xue R Gillmore RH Voss E Morris HJ Stauss, Haematologica 2010 95 126 134 10.3324/haematol.2009.006486 19679884
22. Characterization of conserved CDR3 sequence of TCR - and -chain genes in peripheral blood T cells from patients with diffuse large B-cell lymphoma. Q Yin H Tan S Chen L Yang J Ye Y Li, Hematology 2010 15 48 57 10.1179/ 102453310X12583347009694 20132663
23. IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector. H Mizuguchi Z Xu A Ishii-Watabe E Uchida T Hayakawa, Mol Ther 2000 1 376 382 10.1006/mthe.2000.0050 10933956
24. Exploiting T cell receptor genes for cancer immunotherapy. S Xue R Gillmore A Downs A Tsallios A Holler L Gao V Wong E Morris HJ Stauss, Clin Exp Immunol 2005 139 167 172 10.1111/j.1365-2249.2005.02715.x 15654813
25. Redirecting T lymphocyte specificity by T cell receptor gene transfer - a new era for immunotherapy. B Engels W Uckert, Mol Aspects Med 2007 28 115 142 10.1016/j.mam.2006.12.006 17307249
26. Enhanced anti-tumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. CJ Cohen Y Zhao Z Zheng SA Rosenberg RA Morgan, Cancer Res 2006 66 8878 886 10.1158/0008-5472.CAN-06-1450 16951205
27. Enhanced antitumor activity of T cells engineered to express T cell receptors with a second disulfide bond. CJ Cohen YF Li M El-Gamil PF Robbins SA Rosenberg RA Morgan, Cancer Res 2007 67 3898 3903 10.1158/0008-5472.CAN-06-3986 17440104
28. Influence of codon bias on the expression of foreign genes in microalgae. M Heitzer A Eckert M Fuhrmann C Griesbeck, Adv Exp Med Biol 2007 616 46 53 full-text 18161490
29. Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells. KB Scholten D Kramer EW Kueter M Graf T Schoedl CJ Meijer MW Schreurs E Hooijberg, Clin Immunol 2006 119 135 145 10.1016/j.clim.2005.12.009 16458072
30. Rapid analysis of T-cell selection in vivo using T cell-receptor retrogenic mice. J Holst KM Vignali AR Burton DA Vignali, Nat Methods 2006 3 191 197 10.1038/nmeth858 16489336
31. Enhanced functionality of T cell receptor-redirected T cells is defined by the transgene cassette. M Leisegang B Engels P Meyerhuber E Kieback D Sommermeyer SA Xue S Reuss H Stauss W Uckert, J Mol Med 2008 86 573 583 10.1007/s00109-008-0317-3 18335188
32. Cooperation of human tumor-reactive CD4+ and CD8+T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. J Kuball FW Schmitz RH Voss EA Ferreira R Engel P Guillaume S Strand P Romero C Huber LA Sherman M Theobald, Immunity 2005 22 117 129 10.1016/j.immuni.2004.12. 005 15664164
33. Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells by cell engineering with tumor peptide-specific T-cell receptor genes. T Tsuji M Yasukawa J Matsuzaki T Ohkuri K Chamoto D Wakita T Azuma H Niiya H Miyoshi K Kuzushima Y Oka H Sugiyama H Ikeda T Nishimura, Blood 2005 106 470 476 10.1182/blood-2004-09-3663 15790789
34. WT1 protein-derived, naturally processed 16-mer peptide, WT1 (332), is a promiscuous helper peptide for induction of WT1-specific Th1-type CD4 (+) T cells. F Fujiki Y Oka M Kawakatsu A Tsuboi H Nakajima OA Elisseeva Y Harada Z Li N Tatsumi E Kamino T Shirakata S Nishida Y Taniguchi I Kawase Y Oji HA Sugiyama, Microbiol Immunol 2008 52 591 600 10.1111/j.1348-0421.2008.00080.x 19120973